SinocellTech Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Public

  • Employees
  • 2,300

Employees

  • Stock Symbol
  • 688520

Stock Symbol

  • Share Price
  • $4.45
  • (As of Friday Closing)

SinocellTech General Information

Description

Sinocelltech Group Ltd is one of Chin's biopharma companies specializing in biologics and vaccines. The company's therapeutic areas include oncology, immunology and inflammation, ophthalmology, and prophylactic vaccines. The company has developed technology platforms in protein expression vectors, cell line development, serum-free medium development, stoichiometrically controlled fed-batch cell culture, process scale-up, and protein purification. The capabilities of the company include stable CHO cell line development, cell banking and certification, serum-free and protein-free culture medium development, fed-batch cell culture process development, optimization, and process scale-up, protein purification development, and large scale production.

Contact Information

Formerly Known As
Shenzhou Cell Engineering Co., Ltd., Beijing Shenzhou Cell Biotechnology, Beijing Yiqiao Shenzhou Biotechnology
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Number 31, Kechuang 7th Street
  • Beijing Economic-Technological Development Area
  • Beijing, 100176
  • China
+86 010
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
SHG
Vertical(s)
Corporate Office
  • Number 31, Kechuang 7th Street
  • Beijing Economic-Technological Development Area
  • Beijing, 100176
  • China
+86 010

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SinocellTech Stock Performance

As of 13-Nov-2026, SinocellTech’s stock price is $4.45. Its current market cap is $2.09B with 470M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.45 $4.64 $4.33 - $7.38 $2.09B 470M 2.55M -$0.31

SinocellTech Financials Summary

As of 30-Sep-2026, SinocellTech has a trailing 12-month revenue of $165M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 2,977,962 3,240,326 2,567,924 3,698,552
Revenue 165,404 216,949 350,181 266,768
EBITDA (131,189) (42,004) 51,422 (25,086)
Net Income (138,980) (78,546) 15,602 (55,975)
Total Assets 549,274 546,584 449,856 383,508
Total Debt 424,390 447,840 348,262 387,389
Public Fundamental Data provided by Morningstar, Inc. disclaimer

SinocellTech Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore SinocellTech‘s full profile, request access.

Request a free trial

SinocellTech Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Sinocelltech Group Ltd is one of Chin's biopharma companies specializing in biologics and vaccines. The company's therap
Drug Discovery
Beijing, China
2,300 As of 2026

South San Francisco, CA
 

Abingdon, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

SinocellTech Competitors (18)

One of SinocellTech’s 18 competitors is CytomX Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
Carisma Therapeutics Formerly VC-backed Philadelphia, PA
BioAtla Formerly VC-backed San Diego, CA
BeOne Medicines Formerly PE-Backed Beijing, China
You’re viewing 5 of 18 competitors. Get the full list »

SinocellTech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

SinocellTech ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

37.46 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view SinocellTech’s complete esg history, request access »

SinocellTech FAQs

  • When was SinocellTech founded?

    SinocellTech was founded in 2002.

  • Where is SinocellTech headquartered?

    SinocellTech is headquartered in Beijing, China.

  • What is the size of SinocellTech?

    SinocellTech has 2,300 total employees.

  • What industry is SinocellTech in?

    SinocellTech’s primary industry is Drug Discovery.

  • Is SinocellTech a private or public company?

    SinocellTech is a Public company.

  • What is SinocellTech’s stock symbol?

    The ticker symbol for SinocellTech is 688520.

  • What is the current stock price of SinocellTech?

    As of 13-Nov-2026 the stock price of SinocellTech is $4.45.

  • What is the current market cap of SinocellTech?

    The current market capitalization of SinocellTech is $2.09B.

  • What is SinocellTech’s current revenue?

    The trailing twelve month revenue for SinocellTech is $165M.

  • Who are SinocellTech’s competitors?

    CytomX Therapeutics, Adaptimmune Therapeutics, Carisma Therapeutics, BioAtla, and BeOne Medicines are some of the 18 competitors of SinocellTech.

  • What is SinocellTech’s annual earnings per share (EPS)?

    SinocellTech’s EPS for 12 months was -$0.31.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process